Warning! GuruFocus detected
1 Severe warning sign
with CGEM.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Cullinan Therapeutics Inc
NAICS : 541713
SIC : 2834
ISIN : US2300311063
Share Class Description:
CGEM: Ordinary SharesDescription
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 185.48 | |||||
| Equity-to-Asset | 0.95 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -32.4 | |||||
| 3-Year EPS without NRI Growth Rate | -22.3 | |||||
| 3-Year FCF Growth Rate | -38.9 | |||||
| 3-Year Book Growth Rate | 1.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -4.45 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.56 | |||||
| 9-Day RSI | 37.81 | |||||
| 14-Day RSI | 37.99 | |||||
| 3-1 Month Momentum % | -31.48 | |||||
| 6-1 Month Momentum % | -48.51 | |||||
| 12-1 Month Momentum % | -50.03 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.53 | |||||
| Quick Ratio | 13.53 | |||||
| Cash Ratio | 13.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.7 | |||||
| Shareholder Yield % | -58.78 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -30.39 | |||||
| ROA % | -28.96 | |||||
| ROIC % | -304.87 | |||||
| 3-Year ROIIC % | -170.64 | |||||
| ROC (Joel Greenblatt) % | -6622.69 | |||||
| ROCE % | -35.65 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.74 | |||||
| Price-to-Tangible-Book | 0.74 | |||||
| EV-to-EBIT | -0.33 | |||||
| EV-to-Forward-EBIT | -0.26 | |||||
| EV-to-EBITDA | -0.33 | |||||
| EV-to-Forward-EBITDA | -0.26 | |||||
| EV-to-Forward-Revenue | 4.44 | |||||
| EV-to-FCF | -0.42 | |||||
| Price-to-Net-Current-Asset-Value | 1.14 | |||||
| Price-to-Net-Cash | 1.19 | |||||
| Earnings Yield (Greenblatt) % | -303.03 | |||||
| FCF Yield % | -33.33 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CGEM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cullinan Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.03 | ||
| Beta | -0.21 | ||
| 3-Year Sharpe Ratio | -0.08 | ||
| 3-Year Sortino Ratio | -0.14 | ||
| Volatility % | 76.23 | ||
| 14-Day RSI | 37.99 | ||
| 14-Day ATR ($) | 0.484481 | ||
| 20-Day SMA ($) | 8.4405 | ||
| 12-1 Month Momentum % | -50.03 | ||
| 52-Week Range ($) | 7.2698 - 30.1886 | ||
| Shares Outstanding (Mil) | 58.51 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cullinan Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cullinan Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cullinan Therapeutics Inc Frequently Asked Questions
What is Cullinan Therapeutics Inc(CGEM)'s stock price today?
The current price of CGEM is $7.45. The 52 week high of CGEM is $30.19 and 52 week low is $7.27.
When is next earnings date of Cullinan Therapeutics Inc(CGEM)?
The next earnings date of Cullinan Therapeutics Inc(CGEM) is 2025-05-15 Est..
Does Cullinan Therapeutics Inc(CGEM) pay dividends? If so, how much?
Cullinan Therapeutics Inc(CGEM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers